Fmr Llc ownership in 1VRTX / Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

IT ˙ BIT ˙ US92532F1003

366,30 € ↓ -1,30 (-0,35%)

2026-06-03
AKTIENPREIS

Security	IT:1VRTX / Vertex Pharmaceuticals Incorporated
Institution	Fmr Llc
Latest Disclosed Ownership	9,220,826 shares
Ownership	3.60%

2025-02-12 - Fmr Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 9,220,826 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX). This represents 3.6 percent ownership of the company. In their previous filing dated 2024-02-09 , Fmr Llc had reported owning 12,981,286 shares, indicating a decrease of -28.97 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-02-12	2025-02-12	13G/A	12,981,286	9,220,826	-28.97	3.60	-28.53
2024-02-09	2024-02-09	13G/A	17,876,774	12,981,286	-27.38	5.04	-27.67
2023-02-09	2023-02-09	13G	9,233,569	17,876,774	93.61	6.96	91.79
2022-02-09	2022-02-09	13G/A	13,506,870	9,233,569	-31.64	3.63	-30.09
2021-02-08	2021-02-08	13G/A	24,282,962	13,506,870	-44.38	5.19	-45.00
2020-02-07	2020-02-07	13G/A	20,948,014	24,282,962	15.92	9.44	15.21
2019-02-13	2019-02-13	13G/A	16,923,002	20,948,014	23.78	8.20	22.49
2018-02-13	2018-02-13	13G/A	20,096,787	16,923,002	-15.79	6.69	-17.42
2017-02-14	2017-02-14	13G/A	15,009,184	20,096,787	33.90	8.10	32.65
2016-02-12	2016-02-12	13G/A		15,009,184		6.11
2015-02-13	2015-02-13	13G		14,456,154		6.01
2012-12-10	2012-12-10	13G/A		7,997,637		3.69
2012-02-14	2012-02-14	13G/A		19,383,629		9.29

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,020,265	-192,331	-8.69	902,129	-10.07	0.0094
2026-02-17	2025-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,212,596	-1,091,172	-33.03	1,003,102	-22.47	0.0511
2025-11-13	2025-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	3,303,768	-3,102,604	-48.43	1,293,888	-54.63	0.0673
2025-08-14	2025-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	6,406,372	-1,320,812	-17.09	2,852,116	-23.87	0.1608
2025-05-12	2025-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	7,727,184	-1,491,862	-16.18	3,746,293	0.91	0.2392
2025-02-13	2024-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	9,219,046	-1,305,967	-12.41	3,712,510	-24.16	0.2216
2024-11-13	2024-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	10,525,013	-204,415	-1.91	4,894,973	-2.67	0.2979
2024-08-13	2024-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	10,729,428	55,908	0.52	5,029,097	12.72	0.3219
2024-05-13	2024-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	10,673,520	-2,305,991	-17.77	4,461,638	-15.52	0.2995
2024-02-13	2023-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	12,979,511	-1,380,926	-9.62	5,281,233	5.76	0.4057
2023-11-13	2023-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	14,360,437	-268,229	-1.83	4,993,698	-3.00	0.4316
2023-08-11	2023-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	14,628,666	-1,647,189	-10.12	5,147,974	0.39	0.4316
2023-08-11	2023-03-31	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	16,275,855	-1,590,436	-8.90	5,128,034	-0.61	0.4691
2023-05-11	2023-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,275,855	-1,590,436		5,128,034		0.4691
2023-02-13	2022-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	17,866,291	500,268	2.88	5,159,428	2.61	0.5125
2022-11-10	2022-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	17,366,023	613,012	3.66	5,028,159	6.51	0.5244
2022-08-12	2022-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,753,011	3,571,298	27.09	4,720,832	37.23	0.4704
2022-05-13	2022-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	13,181,713	4,087,860	44.95	3,440,031	72.26	0.2748
2022-02-14	2021-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	9,093,853	4,216,754	86.46	1,997,010	125.74	0.1475
2022-02-14	2021-09-30	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	4,877,099	-956,964	-16.40	884,657	-24.79	0.0702
2021-11-15	2021-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	4,877,099	-956,964		884,657		0.0702
2021-08-13	2021-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,834,063	-4,337,179	-42.64	1,176,322	-46.18	0.0922
2021-05-14	2021-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	10,171,242	-2,972,684	-22.62	2,185,698	-29.64	0.1867
2021-02-08	2020-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	13,143,926	-6,995,070	-34.73	3,106,436	-43.32	0.2764
2020-11-13	2020-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	20,138,996	868,479	4.51	5,480,224	-2.04	0.5539
2020-08-24	2020-06-30	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	19,270,517	-3,386,072	-14.95	5,594,424	3.77	0.6151
2020-08-13	2020-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	19,270,517	-3,386,072		5,594,424		137,438.6263
2020-05-14	2020-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,656,589	-1,204,873	-5.05	5,391,136	3.19	0.7466
2020-02-07	2019-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	23,861,462	-870,552	-3.52	5,224,467	24.69	0.5764
2019-11-13	2019-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	24,732,014	32,099	0.13	4,190,097	-7.49	0.5026
2019-08-13	2019-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	24,699,915	265,756	1.09	4,529,471	0.77	0.5290
2019-05-13	2019-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	24,434,159	3,951,050	19.29	4,494,663	32.42	0.5385
2019-02-13	2018-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	20,483,109	2,411,631	13.34	3,394,256	-2.55	0.4650
2018-11-09	2018-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	18,071,478	1,714,071	10.48	3,483,097	25.29	0.3919
2018-08-10	2018-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,357,407	-927,665	-5.37	2,780,105	-1.31	0.3283
2018-05-14	2018-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	17,285,072	553,239	3.31	2,817,120	12.35	0.3344
2018-02-12	2017-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,731,833	171,388	1.03	2,507,432	-0.41	0.2939
2017-11-13	2017-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,560,445	-1,923,268	-10.41	2,517,851	5.70	0.3044
2017-08-29	2017-06-30	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	18,483,713	-380,935	-2.02	2,381,995	15.47	0.2961
2017-08-11	2017-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	18,483,713	-380,935		2,381,995
2017-05-11	2017-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	18,864,648	-1,232,140	-6.13	2,062,849	39.33	0.2621
2017-02-10	2016-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	20,096,788	-2,840,955	-12.39	1,480,530	-25.99	0.1979
2016-11-14	2016-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,937,743	710,639	3.20	2,000,399	4.62	0.2664
2016-08-11	2016-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,227,104	7,092,351	46.86	1,911,975	58.93	0.2610
2016-05-16	2016-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	15,134,753	125,568	0.84	1,203,062	-36.30	0.1664
2016-02-12	2015-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	15,009,185	-2,679,916	-15.15	1,888,606	2.52	0.2541
2015-11-10	2015-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	17,689,101	1,178,706	7.14	1,842,142	-9.64	0.2622
2015-08-25	2015-06-30	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	16,510,395	1,107,622	7.19	2,038,704	12.20	0.2613
2015-08-13	2015-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	16,510,395			2,038,704
2015-05-14	2015-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	15,402,773	946,619	6.55	1,817,065	5.80	0.2314
2015-02-17	2014-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	14,456,154	435,461	3.11	1,717,391	9.06	0.2235
2014-11-14	2014-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	14,020,693	994,150	7.63	1,574,664	27.67	0.2133
2014-08-14	2014-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	13,026,543	6,417,821	97.11	1,233,353	163.89	0.1653
2014-05-15	2014-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	6,608,722	891,941	15.60	467,369	10.03	0.0649
2014-02-13	2013-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,716,781	-3,311,449	-36.68	424,758	-37.95	0.0600
2013-11-14	2013-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	9,028,230	-634,412	-6.57	684,520	-11.30	0.1049
2013-09-24	2013-06-30	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	9,662,642	9,662,642		771,755		0.1263
2013-08-14	2013-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	9,662,642			771,755		0.1263

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.